Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Kasabach-Merritt syndrome (KMS), also known as hemangioma-thrombocytopenia syndrome, is a rare disorder characterized by profound thrombocytopenia, microangiopathic hemolytic anemia, and subsequent consumptive coagulopathy in association with vascular tumors, particularly kaposiform hemangioendothelioma or tufted angioma.
Features include: Microangiopathic hemolytic anemia, Hyperkalemia, Ventricular arrhythmia, and Low platelet count (thrombocytopenia) and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Microangiopathic hemolytic anemia, Low platelet count (thrombocytopenia) |
Biomarker and diagnostic research for Kasabach-Merritt syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Kasabach-Merritt syndrome.
85 publications have been identified in PubMed for Kasabach-Merritt syndrome. Research spans Case Report / Case Series (60%), Review / Meta-Analysis (10%), and Diagnostic / Biomarker (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 50 | 60% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:50 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Kasabach-Merritt syndrome
1 |
Ventricular arrhythmia |
8 |
10% |
Testing and diagnosis research | 6 | 7% |
Clinical study results | 6 | 7% |
Other research | 4 | 5% |
Laboratory research | 4 | 5% |
Disease patterns and progression | 3 | 4% |
New treatment approaches | 2 | 2% |
Lanzerstorfer D (2026). [PMID: 42026286](https://pubmed.ncbi.nlm.nih.gov/42026286/). *Eur Arch Otorhinolaryngol*. [Case Report / Case Series]
Swaminathan VV (2026). [PMID: 42033477](https://pubmed.ncbi.nlm.nih.gov/42033477/). *Eur J Pediatr*. [Case Report / Case Series]
Zhang Y (2026). [PMID: 41852311](https://pubmed.ncbi.nlm.nih.gov/41852311/). *Pediatr Blood Cancer*. [Other]
Menon R (2026). [PMID: 41728255](https://pubmed.ncbi.nlm.nih.gov/41728255/). *ACG Case Rep J*. [Case Report / Case Series]
Li X (2026). [PMID: 42069257](https://pubmed.ncbi.nlm.nih.gov/42069257/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Sharma SC (2026). [PMID: 42018354](https://pubmed.ncbi.nlm.nih.gov/42018354/). *Ann Plast Surg*. [Case Report / Case Series]
Borfălău CD (2026). [PMID: 41944972](https://pubmed.ncbi.nlm.nih.gov/41944972/). *Vet Res Commun*. [Case Report / Case Series]
Veeser J (2026). [PMID: 41261911](https://pubmed.ncbi.nlm.nih.gov/41261911/). *J Dtsch Dermatol Ges*. [Case Report / Case Series]
Styczewska M (2026). [PMID: 41466529](https://pubmed.ncbi.nlm.nih.gov/41466529/). *Pediatr Blood Cancer*. [Epidemiology / Natural History]
Mahoney MJ (2026). [PMID: 40820232](https://pubmed.ncbi.nlm.nih.gov/40820232/). *Pediatr Dermatol*. [Case Report / Case Series]